Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$2.26 -3.4%	$2.84	$2.06 ▼ $47.70	$6.55M	-0.32	689,242 shs	74,406 shs
ARTL Artelo Biosciences	$9.58 -3.2%	$11.42	$4.92 ▼ $28.60	$6.74M	1.36	291,504 shs	6,662 shs
BCLI Brainstorm Cell Therapeutics	$0.62 -3.9%	$0.95	$0.52 ▼ $5.67	$6.84M	0.12	618,947 shs	14,476 shs
VCNX Vaccinex	$0.53 +26.0%	$0.79	$0.25 ▼ $1.40	$1.38M	1.1	3,066 shs	247 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	-1.68%	-4.10%	-28.66%	-33.52%	-95.56%
ARTL Artelo Biosciences	+1.43%	+1.85%	-33.78%	+73.19%	+30.95%
BCLI Brainstorm Cell Therapeutics	+4.03%	+0.78%	-24.56%	-45.34%	-88.73%
VCNX Vaccinex	-46.10%	-39.77%	-53.62%	-36.05%	-91.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALZN Alzamend Neuro	2.5815 of 5 stars	3.5	2.0	0.0	1.1	3.3	0.6
ARTL Artelo Biosciences	2.8393 of 5 stars	3.8	5.0	0.0	1.4	0.0	0.6
BCLI Brainstorm Cell Therapeutics	2.5043 of 5 stars	0.0	5.0	4.7	2.5	0.8	0.6
VCNX Vaccinex	0.5172 of 5 stars	0.0	4.0	0.0	0.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALZN Alzamend Neuro	3.00	Buy	$180.00	7,864.60% Upside
ARTL Artelo Biosciences	3.60	Strong Buy	$24.00	150.52% Upside
BCLI Brainstorm Cell Therapeutics	2.00	Hold	N/A	N/A
VCNX Vaccinex	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VCNX, ALZN, ARTL, and BCLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/4/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
7/23/2025	BCLI Brainstorm Cell Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/8/2025	ARTL Artelo Biosciences	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/8/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00
6/11/2025	ARTL Artelo Biosciences	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/6/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	$4.95 per share	N/A
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	($2.00) per share	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.36) per share	N/A
VCNX Vaccinex	$388K	3.56	N/A	N/A	($2.59) per share	-0.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALZN Alzamend Neuro	-$4.51M	N/A	0.00	N/A	N/A	N/A	-181.34%	-116.84%	9/10/2025 (Estimated)
ARTL Artelo Biosciences	-$9.83M	-$19.05	N/A	N/A	N/A	N/A	-497.68%	-213.76%	N/A
BCLI Brainstorm Cell Therapeutics	-$11.62M	-$3.10	N/A	N/A	N/A	N/A	N/A	-519.50%	N/A
VCNX Vaccinex	-$20.25M	-$48.27	N/A	∞	N/A	N/A	N/A	-383.58%	N/A

Latest VCNX, ALZN, ARTL, and BCLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
9/10/2025	N/A	ALZN Alzamend Neuro	-$3.69	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	ARTL Artelo Biosciences	-$0.13	-$5.61	-$5.48	-$5.61	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
VCNX Vaccinex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALZN Alzamend Neuro	N/A	6.58	6.58
ARTL Artelo Biosciences	N/A	0.39	0.39
BCLI Brainstorm Cell Therapeutics	N/A	0.21	0.21
VCNX Vaccinex	N/A	0.77	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALZN Alzamend Neuro	49.61%
ARTL Artelo Biosciences	0.87%
BCLI Brainstorm Cell Therapeutics	14.33%
VCNX Vaccinex	50.11%

Insider Ownership

Company	Insider Ownership
ALZN Alzamend Neuro	30.21%
ARTL Artelo Biosciences	5.80%
BCLI Brainstorm Cell Therapeutics	11.15%
VCNX Vaccinex	51.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALZN Alzamend Neuro	4	2.90 million	2.02 million	No Data
ARTL Artelo Biosciences	5	704,000	663,000	Not Optionable
BCLI Brainstorm Cell Therapeutics	40	11.04 million	8.74 million	Optionable
VCNX Vaccinex	40	2.60 million	1.26 million	No Data

VCNX, ALZN, ARTL, and BCLI Headlines

Recent News About These Companies

Vaccinex presents promising cancer treatment data at ASCO

May 29, 2025 | uk.investing.com

Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025

May 29, 2025 | nasdaq.com

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

May 27, 2025 | globenewswire.com

AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets

May 13, 2025 | finanznachrichten.de

AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets

May 13, 2025 | finance.yahoo.com

Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy

April 22, 2025 | markets.businessinsider.com

Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025

April 21, 2025 | quiverquant.comQ

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

April 21, 2025 | globenewswire.com

Vaccinex director resigns, no disagreement cited

March 21, 2025 | investing.com

Vaccinex plans Nasdaq exit as Alzheimer market pressure grows

March 10, 2025 | finance.yahoo.com

Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

March 8, 2025 | finanznachrichten.de

Vaccinex to delist common stock from Nasdaq

March 7, 2025 | markets.businessinsider.com

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

March 7, 2025 | globenewswire.com

Pepinemab by Vaccinex for Alzheimer’s Disease: Likelihood of Approval

December 30, 2024 | pharmaceutical-technology.comP

Vaccinex receives delisting notification from Nasdaq

December 17, 2024 | markets.businessinsider.com

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

December 17, 2024 | markets.businessinsider.com

Vaccinex Shares Tumble 63% On Nasdaq Delisting

December 17, 2024 | marketwatch.com

Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%

December 17, 2024 | finance.yahoo.com

Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock?

December 17, 2024 | benzinga.com

Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards

December 17, 2024 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX, ALZN, ARTL, and BCLI Company Descriptions

Alzamend Neuro NASDAQ:ALZN

$2.26 -0.08 (-3.42%)

Closing price 04:00 PM Eastern

Extended Trading

$2.26 0.00 (-0.22%)

As of 05:22 PM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Artelo Biosciences NASDAQ:ARTL

$9.58 -0.32 (-3.23%)

Closing price 04:00 PM Eastern

Extended Trading

$9.57 -0.01 (-0.09%)

As of 05:10 PM Eastern

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Brainstorm Cell Therapeutics NASDAQ:BCLI

$0.62 -0.03 (-3.88%)

As of 03:33 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Vaccinex NASDAQ:VCNX

$0.53 +0.11 (+26.04%)

As of 01:07 PM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time